Pharma Focus & Neuro-degenerative diseases

Selecting disease modifying drugs for neurodegenerative diseases remains a challenge and participates in the high failure rate for drug development in these indications.  Mitoselect® is a line of  HCA, industry validated, phenotypic models for selection of drug candidates intended to slow or reverse neurodegeneration using PATIENT-DERIVED cell.

These models have proven usefull for the selection of drug candidates currently in Phase I-III clinical trial in diverse indications. Mitoselect® Models are available for Huntington’s disease, Alzheimer’s disease (sporadic), Parkinson’s disease (sporadic) and Parkinson’s disease (LRRK2 mutation).

Why use Mitoselect® models?
  • Identify drugs with disease-modifying potential.
  • Use a well-characterized technology based on mitochondrial behavior assessment.
  • Results are well translated to the clinic, better than using any animal model.
  • Assess drug response heterogeneity using a larger number of donors.
  • A whole R&D team of mitochondrial experts at your service.
Why is Mitoselect® the best tool to target Neurodegenerative diseases ?
  • Mitoselect® uses the proprietary technology Mitostream® to phenotypically quantify and qualify patient derived somatic cells or iPSCs derived cells. 
  • These outcomes can easily be transposed into a response-signature to your drug
  • A customized design to answer your specific need.
CONTACT US FOR A DEMONSTRATION OF MITOSELECT POWER THROUGH THE PAST EXPERIENCE OF OUR CLIENTS
           

Nathalie Compagnone & Clotilde Biscarrat

ncompagnone@icdd-sas.com
cbiscarrat@icdd-sas.com 

tel: +33 484 830 020
Copyright © 2014 ICDD, All rights reserved.


Our mailing address is:
contact@icdd-sas.com


unsubscribe from this list    update subscription preferences